7 drug(s) with this reaction
4,327 total reports
Platelet Count Decreased has been reported as an adverse reaction across 7 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 4,327 adverse event reports mention platelet count decreased in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with platelet count decreased, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have platelet count decreased listed in their FDA adverse event reports, sorted by report count:
In addition to platelet count decreased, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
7 drug(s) manufactured by Amgen Inc have platelet count decreased listed in their FDA adverse event reports: ROMIPLOSTIM, FILGRASTIM, PEGFILGRASTIM, DARBEPOETIN ALFA, EPOETIN ALFA, and others.
There are a combined 4,327 reports of platelet count decreased across 7 Amgen Inc drug(s) in the FDA adverse event database.